Post-Conference Perspectives: CD19-directed CAR-T Cell Therapy in Lymphomas - Episode 3

ZUMA-7: Axicabtagene Ciloleucel as a Second-Line Therapy for LBCL

January 30, 2023

Loretta J. Nastoupil, MD, Marc S. Hoffmann, MD

Loretta J. Nastoupil, MD, reviews data from the ZUMA-7 trial investigating the use of axicabtagene ciloleucel as a second-line therapy for large b-cell lymphoma.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Overview of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)

EP. 2: Currently Available Treatment Options for Patients With R/R DLBCL

Now Viewing

EP. 3: ZUMA-7: Axicabtagene Ciloleucel as a Second-Line Therapy for LBCL

EP. 4: Is There a Potential Role for Rapcabtagene Autoleucel in R/R LBCL?

EP. 5: Selecting the Appropriate CAR T-Cell Therapy for Patients with R/R LBCL

EP. 6: Available Treatment Options for Relapsed/Refractory Follicular Lymphoma (R/R FL)

EP. 7: CAR T-Cell Therapy for Patients With R/R FL

EP. 8: Utilizing CAR T-Cell Therapy in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma